Abpro Holdings announces departure of CEO Ian Chan

Abpro Holdings (ABP) announced the departure of CEO Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, “As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully committed to ABP 102/CT-P72, our joint development with Celltrion, and the other key initiatives driving our growth.” Abpro Chief Medical Officer Robert Markelewicz, Jr., M.D., M.M.Sc., added, “ABP-102/CT-P72 is an extremely exciting development candidate. Initial data presented to date suggest it has a potentially best in class profile in HER2-positive cancers which represent up to 30 percent of all cases of breast, gastric, pancreatic, and other forms of cancer. Along with our partners at Celltrion, we look forward to presenting additional data later this spring at an upcoming scientific meeting.” Miles Suk, concluded by saying, “Dr. Markelewicz and the rest of our focused and determined team will continue to work tirelessly to ensure that our efforts lead to meaningful success. We are dedicated to our mission and confident in delivering lasting value to our partners, investors, and the scientific community.”